|
|
Vaccine Detail
|
Ovarian Cancer Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: Ovarian Cancer Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007131
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Preparation: The vaccine uses naturally processed peptides bound to HLA-A2 molecules expressed in breast and ovarian tumor cell lines (Karkada et al., 2010).
- Description: This is for Ovarian Cancer(NCT00091273). A cancer vaccine comprised of synthetic peptides corresponding to naturally-occurring peptides derived from ovarian cancer cell antigens. Ovarian cancer peptide vaccine may elicit a cytotoxic T-cell response against tumor cells expressing the related ovarian cancer cell antigens (Karkada et al., 2010; NCIT_C48414).
|
| Host Response |
|
|
| References |
Karkada et al., 2010: Karkada M, Weir GM, Quinton T, Sammatur L, MacDonald LD, Grant A, Liwski R, Juskevicius R, Sinnathamby G, Philip R, Mansour M. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(3); 250-261. [PubMed: 20445345].
NCIT_C48414: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48414]
NCT00091273: [https://clinicaltrials.gov/ct2/show/NCT00091273]
|
|
